Previous 10 | Next 10 |
CELLphenomics’ PD3D® tumor model platform will expand Charles River’s portfolio of 3D in vitro testing services Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an agreement with CELLphenomics, a service-based biotech...
2023-12-07 13:53:44 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips In 2016, there were 49 million Americans aged 65 or older. Analysts forecast that will grow to 73 million retirement-age Americans in 2030 and an eye-opening 95 million in the year 2060. ...
Company will perform plasmid DNA production in support of early phase trials for SPG56 Hereditary Spastic Paraplegia Charles River Laboratories International, Inc. (NYSE: CRL) and Genetic Cures for Kids Inc (GC4K), an Australian non-profit foundation focused on research programs and cli...
2023-11-26 09:13:34 ET Summary Charles River Laboratories provides essential products and services to accelerate research and drug development efforts. The company benefits from competitive advantages thanks to the entry barriers, since its clients usually opt for suppliers with g...
New option for cryopreserved leukopaks supports demand of gene-modified cell therapy development and manufacturing Charles River Laboratories International, Inc. (NYSE: CRL) today announced the expansion of its CliniPrime™ suite of Good Manufacturing Practice (GMP)-compliant ...
Strategic partnership includes co-development of patient-derived xenograft (PDX) Digital Twins for in vivo oncology research Charles River to make an equity investment in Aitia as part of the agreement Charles River Laboratories International, Inc. (NYSE: CRL) and Aitia , ...
2023-11-09 18:19:22 ET Summary Charles River Laboratories' shares have fallen 21% this year and dropped 4% after a mixed earnings report. The company beat earnings expectations but revised its revenue growth and EPS guidance downward. Charles River is struggling to secure new ...
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 19 scientific posters, both independently and collaboratively with clients, at Neuroscience 2023, the annual meeting of the Society for Neuroscience (SfN). ...
2023-11-08 11:17:02 ET Charles River Laboratories International, Inc. (CRL) Q3 2023 Earnings Conference Call November 08, 2023 08:30 AM ET Company Participants Todd Spencer - Vice President, Investor Relations Jim Foster - Chairman, President & Chief Executive Of...
2023-11-08 07:01:17 ET More on Charles River Laboratories Charles River Laboratories: Diving Into The Lab (Rating Upgrade) Charles River Laboratories Q3 2023 Earnings Preview Charles River falls on Investor Day amid growth concerns Seeking Alpha’s Quan...
News, Short Squeeze, Breakout and More Instantly...
Charles River Laboratories International Inc. Company Name:
CRL Stock Symbol:
NYSE Market:
Lentiviral vector CDMO collaboration to support advanced cell therapies for hematological cancers Charles River Laboratories International, Inc. (NYSE: CRL) and the Gates Institute at the University of Colorado Anschutz Medical Campus today announced a lentiviral vector contract...
2024-06-18 18:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Leveraging CGT CDMO expertise to support T-cell immunotherapy clinical trial Charles River Laboratories International, Inc. (NYSE: CRL) and Captain T Cell, a spinoff from the renowned Max Delbrück Center Berlin, Germany, today announced a plasmid DNA and retrovirus vector productio...